Immix Biopharma Form 4: CFO Gabriel Morris Adds to Stake
Rhea-AI Filing Summary
Form 4 overview: Immix Biopharma, Inc. (ticker: IMMX) filed a Form 4 reporting an open-market purchase by Chief Financial Officer and Director Gabriel S. Morris on 18 June 2025.
- Transaction details: Mr. Morris bought 2,225 common shares at a volume-weighted average price of $2.279 per share (code “P”).
- Direct ownership after transaction: 288,059 common shares held in his own name (ownership code “D”).
- Indirect ownership: 270,844 shares held through Alwaysraise LLC and 24,141 shares held through Alwaysraise Ventures I LP (ownership code “I”). For both entities, Mr. Morris disclaims beneficial ownership except to the extent of his pecuniary interest.
- No derivative securities were reported in Table II.
- The filing was electronically signed by Mr. Morris on 20 June 2025.
The Form 4 reflects Mr. Morris’ latest equity position and provides investors with an updated view of insider holdings as of 18 June 2025.
Positive
- CFO & Director open-market purchase: 2,225 shares acquired at $2.279, increasing direct holdings to 288,059 shares.
- Significant cumulative insider exposure: Filing shows over 580k shares reported across direct and indirect ownership vehicles.
Negative
- Purchase size is modest: only 2,225 shares bought, a small increment relative to existing holdings.
- No new derivative activity disclosed: absence of option exercises or other instruments limits insight into long-term incentive alignment.
Insights
TL;DR: CFO bought 2,225 IMMX shares at $2.279, lifting direct stake to 288,059; indirect holdings unchanged.
The filing shows a small open-market purchase by the company’s CFO and Director, executed at a sub-$3 share price. Although modest in size, the purchase increases his direct stake to roughly 288 k shares, while total reported influence (direct + indirect) remains above 580 k shares. No options or other derivatives were exercised, and the transaction was coded “P,” confirming it was a straightforward buy. Investors monitoring insider activity may view updated ownership levels as useful for assessing alignment, but the purchase does not materially alter overall insider ownership percentages.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 2,225 | $2.279 | $5K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Volume-weighted average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by Alwaysraise, except to the extent of his pecuniary interest therein. Gabriel Morris is the Managing Partner of Alwaysraise Ventures I Investments, LLC ("Alwaysraise Ventures"), the general partner of Alwaysraise Ventures I, LP. ("AVILP") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by AVILP, except to the extent of his pecuniary interest therein.
